OCUL
Ocular Therapeutix, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +3.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 70.61K | $537,539 | n/a | n/a |
| Q2 2026 | 90 | -7 | 115.87M | $1.14B | +4 | −12 |
| Q1 2026 | 101 | +4 | 114.41M | $983.07M | +11 | −8 |
| Q4 2025 | 96 | +1 | 115.21M | $1.40B | +2 | n/a |
| Q3 2025 | 18 | 0 | 82.57M | $965.26M | +1 | −1 |
| Q2 2025 | 15 | +1 | 57.50M | $533.65M | +1 | n/a |
| Q1 2025 | 11 | 0 | 20.34M | $149.08M | +1 | −1 |
| Q4 2024 | 11 | +1 | 19.58M | $167.25M | +2 | −1 |
| Q3 2024 | 9 | +1 | 15.07M | $131.15M | +1 | n/a |
| Q2 2024 | 8 | n/a | 16.30M | $111.49M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 5.20M | +44.4% | $38.12M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 4.81M | +8.0% | $35.27M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 3.42M | +5.8% | $25.09M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 3.39M | -2.8% | $24.86M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Point72 Asset Management ✦ | 1.94M | -33.8% | $14.24M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 461.23K | +82.3% | $3.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 454.00K | New | $3.33M | 0.0% | New | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 452.96K | -3.1% | $3.32M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 9 | T. Rowe Price ✦ | 125.74K | -80.3% | $922,000 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 60.12K | +91.4% | $440,702 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 15.65K | -40.5% | $114,714 | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $3.33M | 0.0% |
Exited
| Millennium Management | $3.82M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 266 holders, 206.22M shares, $1.70B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.98K sh · $87,363
Officer · 10.87K sh · $76,626
Officer · 9.99K sh · $70,430
Officer · 3.04K sh · $32,687
Officer · 3.30K sh · $35,531
Officer, Director · 21.65K sh · $233,160
Officer · 1.90K sh · $20,450
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology